Merck To Discontinue Development Of SARS-CoV-2 Vaccine Candidates Based On Phase 1 Study Findings

Financial world news, market analysis, investment scam prevention tips and more ✔️ Learn all there is to know about the asset management industry. This magazine is crafted specifically for those who are interested in diving into the global asset management world. (RTTNews) - Merck (MRK) has decided to discontinue development of the company's COVID-19 vaccine candidates, V590 and V591. In phase 1 clinical studies, both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines. To keep reading about Merck To Discontinue Development Of SARS-CoV-2 Vaccine Candidates Based On Phase 1 Study Findings, Click on the link. Seoul, Korea
http://dlvr.it/RrHsMx

Comments

Post a Comment

Popular posts from this blog

US intel chief rebukes lawmakers over 'pandemic' of leaks

Image
WASHINGTON (AFP) - US intelligence chief John Ratcliffe on Sunday (Aug 30) defended his move to end in-person election security briefings to Congress, blaming a "pandemic" of leaks from lawmakers. The Director of National Intelligence wrote to top lawmakers from both parties in the House and Senate intelligence committees on Friday explaining the change. The announcement sparked accusations from senior Democrats that the administration was covering up Russian help for President Donald Trump's re-election bid. Ratcliffe voiced frustration over leaks from a counterintelligence briefing to Congress a month ago informing lawmakers that China, Russia and Iran were all seeking to interfere. "And yet, within minutes of that... a number of members of Congress went to a number of different publications and leaked classified information," Ratcliffe told Fox News. He said the leakers aimed to "create a narrative that simply isn't true, that somehow Russia is a gre...
Read more

New Data Suggest ExoFlo is Poised for a Quantum Leap in the Fight Against COVID-19

Image
AUSTIN, Texas, Aug. 27, 2020 /PRNewswire/ -- Direct Biologics, LLC announces a rapid acceleration of the investigational use of ExoFlo™ for treatment of COVID-19 as new mechanisms of SARS-CoV-2 have been revealed. Published in Lung Cellular and Molecular Physiology in August, a recent research collaboration by bioinformatics experts in the United States and Poland suggests that the SARS-CoV-2 viral genome may be binding to specific human microRNA (miRNA) in the manner of an epigenetic "sponge"— essentially inhibiting normal downstream processes and facilitating viral hijacking and/or immune evasion. "These findings are highly interesting and pertinent to our research," states Dr. Vik Sengupta, Chief Medical Officer, "especially since the authors' exomic analysis reveals the depletion of multiple miRNA targets. These data complement our recent findings that ExoFlo contains multiple miRNA that may specifically inhibit the SARS-CoV-2 viral invasion and modulat...
Read more

New Philadelphia Digital Agency Makes Its Public Debut

Image
PHILADELPHIA, Aug. 26, 2020 /PRNewswire/ -- Moxie Labs, a digital marketing & product development agency located in Philadelphia, PA, is making its debut. The agency is co-founded by Justin Mathews (CEO) and Mike O'Malley (CIO), industry veterans who have spent the majority of their careers navigating the city's technology and marketing sectors.  O'Malley worked for prominent marketing agencies such as MedManage Systems & Aptus Health, and eventually went on to build out his own shop, Elevation Agency. Mathews went down a management and business development route in the Philadelphia technology industry and worked for a few local notables such as Refinery, Tonic Design, and most recently, O3 World. The two entrepreneurs had long been aware of the intersection of marketing and technology in the business world. When discussing the possibility of starting a new business venture, they decided to build a new agency that recognized the importance of both niches for modern ...
Read more